Q1 Earnings Forecast for DNLI Issued By B. Riley

Denali Therapeutics Inc. (NASDAQ:DNLI) – B. Riley issued their Q1 2025 earnings estimates for Denali Therapeutics in a report issued on Friday, November 8th. B. Riley analyst M. Mamtani forecasts that the company will earn ($0.77) per share for the quarter. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.62) per share. B. Riley also issued estimates for Denali Therapeutics’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($2.26) EPS and FY2027 earnings at ($1.20) EPS.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the business posted ($0.72) EPS.

Several other analysts have also recently weighed in on the stock. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Wedbush reduced their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Citigroup boosted their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Denali Therapeutics in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Price Performance

DNLI stock opened at $29.89 on Monday. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.33. The firm has a market capitalization of $4.30 billion, a P/E ratio of -10.83 and a beta of 1.40. The business’s 50-day moving average is $28.05 and its two-hundred day moving average is $23.84.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. MONECO Advisors LLC raised its position in Denali Therapeutics by 4.6% during the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after buying an additional 400 shares during the last quarter. Assetmark Inc. raised its holdings in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares in the last quarter. CWM LLC raised its holdings in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after purchasing an additional 920 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Denali Therapeutics by 5.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after purchasing an additional 1,372 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the transaction, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,578 shares of company stock worth $2,474,440. 7.90% of the stock is owned by insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.